Optos
LONDON, UK, 16 April 2008 – Optos plc (LSE: OPTS), a leading medical technology company for the design, development, manufacturing and marketing of retinal imaging devices, is today announcing that it has launched a new retinal imaging device - the P200C. The device is designed to meet the need for more exacting clinical imaging capabilities and standards within the ophthalmology market and at optometric practices that are clinically managing a patient base with advanced ocular disease.
Key distinguishing features include directed eye steering that allows the doctor to obtain a set of images that extend beyond the normal field of view by potentially reaching the ora serrata, which marks the extreme limit or boundary of the retina. This is clinically accepted as being very difficult to observe with conventional examination techniques. An additional benefit is an ergonomic patient interface that uses automatic iris recognition which will improve practice productivity and image accuracy.
Optos has now commercialised a full range of complementary retinal imaging devices that support different customer segments and patient levels within the eye and healthcare market:
- P200 is concentrated on wellness screening carried out by optometrists and ophthalmologists;
- P200C in the advanced clinical optometry and ophthalmology markets;
- P200MA supports doctors through an advanced medical angiography procedure.
All three devices provide practitioners with the benefit of an ultra wide-field view of the retina, each facilitating the clinical detection, diagnosis and management of both eye and non-eye diseases.
Commenting on the benefits of the new device, Sanjeev Nath, MD, New York, NY, said:
“The P200C will redefine ocular disease management by simultaneously delivering ultra high resolution and wide-field views which is ideal for managing patients with pathology. The images produced by the P200C are stellar with great image quality in the mid to very far periphery and with great resolution in the central pole.”
Thomas W. Butts, Chief Executive Officer, Optos plc, said:
“We are very pleased to have expanded our product offering in a way that responds uniquely and directly to practice and patient needs in general ophthalmology and advanced clinical optometry. Feedback from doctors on the ease of use and the clinical enhancement that the device confers has been extremely positive and we look forward to marketing the P200C primarily on a pay-per-patient basis to an estimated 10,000 addressable practice locations in our existing markets.”